Ultomiris Available Soon for Eligible aHUS Patients in England

Ultomiris Available Soon for Eligible aHUS Patients in England

295091

Ultomiris Available Soon for Eligible aHUS Patients in England

Alexion Pharmaceuticals’ long-acting Ultomiris (ravulizumab) was added to the list of medications available through England’s national health service (NHS) to adults and children weighing at least 10 kilograms (22 pounds), with atypical hemolytic uremic syndrome (aHUS). Ultomiris is Alexion’s successor to Soliris (eculizumab) — also approved for aHUS and given every other week — and allows for an eight-week dosing schedule after a loading phase. While both therapies block the activity of the complement C5 protein, preventing the…

You must be logged in to read/download the full post.